WALTHAM,
Mass., Oct. 30, 2023 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology
company advancing a pipeline of antibody therapeutics with the
potential to transform the treatment of inflammatory bowel disease
("IBD"), today announced that management will participate in the
following investor conferences:
- Guggenheim 5th Annual Inflammation & Immunology
Conference, New York, New York –
November 7th, 2023
- Stifel 2023 Annual Healthcare Conference, New York, New York – November 14th, 2023
- Jefferies 2023 London Healthcare Conference, London, UK – November
15-16th, 2023
To access the webcast of Aeglea's presentations, please visit
the "Events & Presentations" page within the Investors section
of the Aeglea website at ir.aeglea.com.
About Aeglea BioTherapeutics
In June 2023, Aeglea completed its asset acquisition
of Spyre and shifted its disease focus to IBD. Aeglea is advancing
a pipeline of antibody therapeutics with the potential to transform
the treatment of IBD. Aeglea's approach combines novel
antibody engineering, rational therapeutic combinations, and
precision immunology with the goal of maximizing efficacy, safety,
and convenience of treatments for IBD. The company is developing
antibodies targeting α4β7, TL1A, and IL-23.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-upcoming-november-investor-conferences-301972037.html
SOURCE Aeglea BioTherapeutics, Inc.